Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $141 thousand versus the consensus estimate of $61.6 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.